Table 4.

Subgroup analysis comparing the efficacy of low-dose RTX and other NSISs.

n = 20	ARR	EDSS	VFSS	Length of spinal cord lesion
NSISs	0.66 ± 0.51	3.65 ± 1.22	2.10 ± 2.02	5.68 ± 3.73
Low-dose RTX	0.08 ± 0.26	3.40 ± 1.99	2.05 ± 2.01	4.21 ± 3.58
Significance	0.000	0.039	0.33	0.006*

^*Data from 19 cases were analyzed, 1 patient died, and no recent MRI was available.

NSISs, non-steroidal immunosuppressants; ARR, annualized relapse rate; EDSS, expanded disability status scale; VFSS, visual function system scale; RTX, rituximab.